NYSE:SYK - Stryker Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $167.81 -5.05 (-2.92 %) (As of 12/14/2018 01:50 PM ET)Previous Close$172.86Today's Range$167.53 - $171.6052-Week Range$146.80 - $179.84Volume33,304 shsAverage Volume1.29 million shsMarket Capitalization$64.59 billionP/E Ratio25.94Dividend Yield1.09%Beta0.66 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products that include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. It also provides spinal implant products comprising cervical, thoracolumbar, and interbody systems for use in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned sales subsidiaries and branches, as well as third-party dealers and distributors in approximately 85 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan. Receive SYK News and Ratings via Email Sign-up to receive the latest news and ratings for SYK and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:SYK Previous Symbol CUSIP86366710 Webwww.strykercorp.com Phone269-389-2600 Debt Debt-to-Equity Ratio0.60 Current Ratio1.91 Quick Ratio1.21 Price-To-Earnings Trailing P/E Ratio25.94 Forward P/E Ratio23.05 P/E Growth2.37 Sales & Book Value Annual Sales$12.44 billion Price / Sales5.05 Cash Flow$8.0717 per share Price / Cash Flow20.79 Book Value$26.67 per share Price / Book6.29 Profitability EPS (Most Recent Fiscal Year)$6.49 Net Income$1.02 billion Net Margins9.31% Return on Equity28.00% Return on Assets12.26% Miscellaneous Employees33,000 Outstanding Shares374,190,000Market Cap$64.59 billion OptionableOptionable Stryker (NYSE:SYK) Frequently Asked Questions What is Stryker's stock symbol? Stryker trades on the New York Stock Exchange (NYSE) under the ticker symbol "SYK." How often does Stryker pay dividends? What is the dividend yield for Stryker? Stryker declared a quarterly dividend on Tuesday, December 4th. Investors of record on Monday, December 31st will be paid a dividend of $0.52 per share on Thursday, January 31st. This represents a $2.08 annualized dividend and a yield of 1.24%. The ex-dividend date of this dividend is Friday, December 28th. This is an increase from Stryker's previous quarterly dividend of $0.47. View Stryker's Dividend History. How were Stryker's earnings last quarter? Stryker Co. (NYSE:SYK) announced its quarterly earnings results on Thursday, October, 25th. The medical technology company reported $1.69 EPS for the quarter, beating the Zacks' consensus estimate of $1.68 by $0.01. The medical technology company earned $3.24 billion during the quarter, compared to the consensus estimate of $3.26 billion. Stryker had a net margin of 9.31% and a return on equity of 28.00%. View Stryker's Earnings History. When is Stryker's next earnings date? Stryker is scheduled to release their next quarterly earnings announcement on Tuesday, January 29th 2019. View Earnings Estimates for Stryker. What guidance has Stryker issued on next quarter's earnings? Stryker issued an update on its fourth quarter 2018 earnings guidance on Thursday, October, 25th. The company provided earnings per share (EPS) guidance of $2.13-2.18 for the period, compared to the Thomson Reuters consensus estimate of $2.13. Stryker also updated its FY 2018 guidance to $7.25-7.30 EPS. What price target have analysts set for SYK? 23 equities research analysts have issued 12 month price objectives for Stryker's stock. Their forecasts range from $165.00 to $200.00. On average, they anticipate Stryker's stock price to reach $181.8571 in the next year. This suggests a possible upside of 8.4% from the stock's current price. View Analyst Price Targets for Stryker. What is the consensus analysts' recommendation for Stryker? 23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last year. There are currently 8 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stryker. What are Wall Street analysts saying about Stryker stock? Here are some recent quotes from research analysts about Stryker stock: 1. According to Zacks Investment Research, "Stryker outperformed the industry in a year’s time. The company continues to gain from its Mako robotics platform, which has been the key driver of its core Orthopaedic segment. In fact, the company witnessed solid growth in Mako robot installations in recent times. Surging domestic sales is another positive. Moreover, solid performance in emerging markets and Europe paints a bright picture. Solid expansion in operating margin is encouraging as well. A raised guidance for 2018 buoys optimism. On the flip side, Stryker’s gross margin has been declining. Total debt on the balance sheet remains unchanged, adding to the company’s woes. The Trauma & Extremities business had moderate growth lately as it was affected by softness in the market and product supply issues. Stiff competition in the MedTech space is likely to mar Stryker’s prospects. " (12/12/2018) 2. Needham & Company LLC analysts commented, "We attended at its Orthopaedics facility in on 11/8/18. We highlight some of our take-aways from the event below." (11/9/2018) 3. BTIG Research analysts commented, "Adding Photonics to its Instrument Offerings This morning, Stryker announced the acquisition of Invuity (IVTY, Not a share in all cash, for a deal value of ~$190M. With TTM sales of $40.8M, the deal multiple comes in at ~4.7x, in line with previous SYK acquisitions. The IVTY portfolio of photonic illuminated retractors will add to Stryker’s product offering in a variety of areas such as nipple- sparing mastectomies, anterior hip procedures, as well as general surgery and other areas. We believe the IVTY products will compliment Stryker’s existing visualization and illumination product portfolio modestly. That said, while IVTY offered a novel technology, the company was challenged to independently gain broader adoption as a stand-alone technology beyond a specific subset of procedures where proper illumination was not achieved with overhead exterior surgical field lighting." (9/12/2018) Has Stryker been receiving favorable news coverage? Headlines about SYK stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Stryker earned a coverage optimism score of 1.8 on InfoTrie's scale. They also gave media headlines about the medical technology company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an impact on the company's share price in the near future. Who are some of Stryker's key competitors? Some companies that are related to Stryker include 3M (MMM), Becton Dickinson and (BDX), Boston Scientific (BSX), Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ResMed (RMD), ABIOMED (ABMD), Teleflex (TFX), DexCom (DXCM), Hill-Rom (HRC), Haemonetics (HAE), Insulet (PODD), ICU Medical (ICUI), Globus Medical (GMED) and Penumbra (PEN). Who are Stryker's key executives? Stryker's management team includes the folowing people: Mr. Kevin A. Lobo, Chairman & CEO (Age 53)Mr. Timothy J. Scannell, Pres & COO (Age 53)Mr. Glenn S. Boehnlein, VP & CFO (Age 56)Mr. Lonny J. Carpenter, Group Pres & Adviser to the CEO (Age 56)Mr. David K. Floyd, Group Pres & Advisor to the CEO (Age 57) Who are Stryker's major shareholders? Stryker's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc (6.81%), BlackRock Inc. (6.39%), Greenleaf Trust (6.08%), Capital Research Global Investors (3.88%), Bank of New York Mellon Corp (2.03%) and Massachusetts Financial Services Co. MA (1.90%). Company insiders that own Stryker stock include Bijoy Sagar, David Floyd, Glenn S Boehnlein, Graham A Mclean, Howard E Cox Jr, Katherine Ann Owen, Kevin Lobo, Lonny J Carpenter, Louise Francesconi, M Kathryn Fink, Roch Doliveux, Ronda E Stryker, Timothy J Scannell, William E Berry Jr and Yin C Becker. View Institutional Ownership Trends for Stryker. Which major investors are selling Stryker stock? SYK stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Massachusetts Financial Services Co. MA, Point72 Asset Management L.P., BlackRock Inc., TIAA CREF Investment Management LLC, Morgan Stanley, Mitsubishi UFJ Trust & Banking Corp and Bank of New York Mellon Corp. Company insiders that have sold Stryker company stock in the last year include Bijoy Sagar, David Floyd, Glenn S Boehnlein, Graham A Mclean, Howard E Cox Jr, Katherine Ann Owen, Kevin Lobo, Lonny J Carpenter, M Kathryn Fink, William E Berry Jr and Yin C Becker. View Insider Buying and Selling for Stryker. Which major investors are buying Stryker stock? SYK stock was bought by a variety of institutional investors in the last quarter, including Capital International Investors, Capital World Investors, Winslow Capital Management LLC, Alliancebernstein L.P., HealthCor Management L.P., Mackenzie Financial Corp, Schroder Investment Management Group and The Manufacturers Life Insurance Company. View Insider Buying and Selling for Stryker. How do I buy shares of Stryker? Shares of SYK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Stryker's stock price today? One share of SYK stock can currently be purchased for approximately $167.81. How big of a company is Stryker? Stryker has a market capitalization of $64.59 billion and generates $12.44 billion in revenue each year. The medical technology company earns $1.02 billion in net income (profit) each year or $6.49 on an earnings per share basis. Stryker employs 33,000 workers across the globe. What is Stryker's official website? The official website for Stryker is http://www.strykercorp.com. How can I contact Stryker? Stryker's mailing address is 2825 AIRVIEW BLVD, KALAMAZOO MI, 49002. The medical technology company can be reached via phone at 269-389-2600 or via email at [email protected] MarketBeat Community Rating for Stryker (NYSE SYK)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 649 (Vote Outperform)Underperform Votes: 637 (Vote Underperform)Total Votes: 1,286MarketBeat's community ratings are surveys of what our community members think about Stryker and other stocks. Vote "Outperform" if you believe SYK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/14/2018 by MarketBeat.com StaffFeatured Article: What is a Roth IRA?